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ABSTRACT
Runx1 participation in epithelial mammary cells is still under review. Emerging 
data indicates that Runx1 could be relevant for breast tumor promotion. However, 
to date no studies have specifically evaluated the functional contribution of Runx1 
to control gene expression in mammary epithelial tumor cells. It has been described 
that Runx1 activity is defined by protein context interaction. Interestingly, Foxp3 is 
a breast tumor suppressor gene. Here we show that endogenous Runx1 and Foxp3 
physically interact in normal mammary cells and this interaction blocks Runx1 
transcriptional activity. Furthermore we demonstrate that Runx1 is able to bind 
to R-spondin 3 (RSPO3) and Gap Junction protein Alpha 1 (GJA1) promoters. This 
binding upregulates Rspo3 oncogene expression and downregulates GJA1 tumor 
suppressor gene expression in a Foxp3-dependent manner. Moreover, reduced 
Runx1 transcriptional activity decreases tumor cell migration properties. Collectively, 
these data provide evidence of a new mechanism for breast tumor gene expression 
regulation, in which Runx1 and Foxp3 physically interact to control mammary 
epithelial cell gene expression fate. Our work suggests for the first time that Runx1 
could be involved in breast tumor progression depending on Foxp3 availability. 
INTRODUCTION
The RUNX proteins belong to a family of 
transcription factors (RUNX1, 2 and 3) known to 
play crucial roles in hematopoiesis, osteogenesis 
and neurogenesis [1]. RUNX1 activity has been 
comprehensively study in physiological and tumor contexts 
[2, 3]. It has a runt domain and is able to bind a common TG 
(T/C)GGT consensus binding site, inducing proliferation 
in a context-dependent manner [4–6]. Moreover, RUNX1 
is considered as a multifaceted protein that associates 
with diverse partners to direct different biological 
outcomes [2]. In particular Runx1 has both transcriptional 
activation and inhibition domains that allow it to bind 
a plethora of co-factors, such as the tumor suppressor 
gene Foxp3, which in turn modulates Runx1’s regulatory 
effect [7, 8]. Sakaguchi and colleagues showed that 
Foxp3 transcription factor inhibits Runx1 transcriptional 
activity by protein-protein interaction promoting 
the suppressive function of regulatory T cells [8]. 
In human breast cancer, Runx1 activity is still matter of 
debate and little is known about its direct role in breast 
cancer progression [9–12]. Interestingly, Ferrari and 
colleagues have shown using multivariate analysis that 
high expression of RUNX1 correlates with poor prognosis 
in triple negative human breast cancer and strongly suggest 
that Runx1 could be used as an independent prognostic 
marker in this subgroup of human breast cancer [13]. 
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Foxp3 is an X-linked tumor suppressor gene 
expressed in the normal mammary gland, but 
downregulated, mutated or cytoplasmically localized in 
mammary tumor cells [14–18]. It has been shown that in 
normal cells, wild-type FOXP3 is bound to the promoter 
and transcriptionally repress human epidermal growth 
factor receptor Her-2/Neu and miR-146a promoters, 
transcriptionally repressing expression of these mediators 
that are involved in mammary tumorigenesis [15, 19]. 
Moreover, FOXP3 overexpression in human cancer cell 
lines was shown to repress tumor growth and metastasis 
[15, 19, 20].
This context encouraged us to investigate if Runx1 
is able to modulate gene expression in mammary tumor 
cells, and whether this activity could be modulated by 
Foxp3 in normal epithelial cells. To achieve this goal, 
we investigated Runx1 and Foxp3 participation in the 
regulation of expression of two tumor associated genes, 
Rspo3 [21, 22] and GJA1 [23, 24], which are known 
modulators of breast tumor cell growth (positively and 
negatively, respectively). Both promoter regions possess 
Runx1 binding sites, but no Foxp3-binding regions were 
detected in their proximity. Runx1 is able to promote 
RSPO3 gene expression and inhibit GJA1 gene expression 
on tumor epithelial cells, depending on Foxp3 availability. 
Our results show, for the first time, that Foxp3 thwarts 
Runx1 activity through physical interaction in mammary 
epithelial cells. Furthermore, these data suggest that 
Runx1 might modulate mammary gland tumorigenesis 
depending on Foxp3 expression levels unraveling a new 
mechanism of gene expression regulation on mammary 
epithelial cells.
RESULTS
Runx1 activates RSPO3 oncogene expression in 
tumor cells
R-spondin protein 3 (RSPO3) belongs to a family 
of secreted proteins that strongly potentiates Wnt/
βcatenin signaling [25, 26] and regulates tissue patterning 
and differentiation [27, 28]. In particular, RSPO3 has 
been described as a potent oncogene due to its ability to 
transform and generate mammary tumors in vivo after 
inoculation of RSPO3-transduced epithelial mammary 
cells [22]. Furthermore, we and other laboratories, 
described that MMTV-induced mammary gland tumors 
express high levels of RSPO3 compared with virgin 
normal mammary gland [21, 22]. To address the question 
of how this oncogene expression is differentially regulated 
in normal and tumor mammary epithelial cells, we analyze 
the promoter region of RSPO3. In silico analysis of Rspo3 
promoter region (1500 bp upstream from +1 transcription 
start site) revealed three putative binding sites for the 
transcription factor Runx1: two of high affinity (TG (T/C)
GGT) and one of low affinity (AGTGGT) (Supplementary 
Table 1). While, no Foxp3 binding sites (A/GTAAACAA) 
were found. 
We then investigated the potential role of Runx1 
in the regulation of Rspo3 gene expression, in the LM3 
cell line, which was derived from a spontaneous BALB/c 
mouse mammary tumor [29]. LM3 cells can generate 
metastatic tumors when inoculated into syngeneic mice 
[30]. The LM3 cell line expresses detectable levels 
of Rspo3 mRNA (Supplementary Figure 1) and a 
transcriptionally active form of Runx1, which binds to the 
consensus sequence found in the Rspo3 promoter region 
(Figure 1A–1B and Figure 2B). In the gel shift assay the 
signal intensity decreases when cold oligonucleotide is 
included in the reaction (Figure 1B, 1C lane versus 32P lane) 
showing the specificity of the DNA-protein binding. 
Furthermore, when nuclear extracts were co-incubated 
with the labelled probe and an anti-Runx1 antibody, the 
intensity of the band decreased (Figure 1B, 1AB lane 
versus 32P lane), probably because the antibody interferes 
with Runx1 DNA binding domain. These results suggest 
that endogenous Runx1 is able to bind its putative binding 
site in the rspo3 promoter. 
To evaluate if the observed DNA/Runx1 interaction 
is biologically relevant for Rspo3 expression, we altered 
Runx1 expression levels in tumor and normal cell lines 
and evaluated Rspo3 expression and cell behaviour 
changes. Runx1 transcriptional activity was reduced by 
expression of the dominant-negative (DN) form of Runx1 
in LM3 and MDA-DB-231 tumor cells [31]. We observed 
a significant reduction of Runx1 transcriptional activity 
in DN/Runx1 transfected tumor cells (Figure 2A and 2B), 
which resulted in a significant downregulation of Rspo3 
expression and secretion (Figure 2C–2E: LM3 cell line 
and 2F: MDA-MB-231 cell line). On the other hand, we 
transfected SCp2 non-tumor epithelial mammary cells 
with an expression vector containing the full length cDNA 
sequence of Runx1 down-stream of a CMV-promoter [32]. 
Figure 2G shows that overexpression of Runx1 in these 
cells induced significant upregulation of Rspo3 expression. 
These experiments demonstrate that Runx1 is able to bind 
to Rspo3 promoter and triggers the expression of this 
oncogene in mammary epithelial cells. 
Runx1 and Foxp3 physically interact in normal 
mammary epithelial cells
It has been previously shown that Foxp3 can 
interact with Runx1 and block its transcriptional activity 
in regulatory T cells [8]. Normal mammary epithelial 
cells express higher functional levels of Foxp3 compared 
to tumor cells [15] and comparable levels of endogenous 
Runx1 mRNA (Supplementary Figure 1A). To investigate 
if Foxp3 is able to modulate Runx1 transcriptional activity 
in normal mammary cells, we first explored whether 
endogenous Runx1 and Foxp3 proteins physically interact 
in these cells. To address this question we performed co-
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immunoprecipitation assays in which total protein extracts 
from SCp2 cells were incubated with anti-Foxp3 antibody 
and the precipitated proteins were immunoblotted with an 
anti-Runx1 antibody. Figure 3A shows a band of 50KDa 
corresponding to Runx1 molecular weight in the IP lane 
(co-immunoprecipitated proteins). Furthermore, Figure 3B 
shows that endogenous Runx1 and Foxp3 are concentrated 
in the nuclear compartments. In addition, partial co-
localization of these two proteins in SCp2 cell nuclei is 
observed (Figure 3B). Therefore, these studies indicate 
that Runx1 and Foxp3 proteins physically interact in this 
mammary epithelial cell line. 
Figure 1: Runx1 binds to Rspo3 promoter. (A) ChIP assays were performed on LM3 cells using specific ChIP-grade Runx1 antibody 
or control IgG antibody. Specific primers were designed for targeting Runx1 high affinity binding site in the Rspo3’s promoter region. 
Bar graph shows mean and standard deviation (SD) of three independent experiments each of them performed by triplicate. Primers for 
Gapdh promoter region were used as negative control with no amplification product. (B–C) Gel shift assays were performed on LM3 (B) 
or SCp2 (C) nuclear extracts using an oligoprobe containing Runx1 consensus sequence included in the Rspo3 promoter region (–490bp) 
(lane 32P and lane Ab). This band showed lower intensity when cold oligonucleotides were included in the reaction (lane C). Asterisks in the 
Figure show unspecific binding. 32P: phospho-labeled oligoprobe, Ab: anti-Runx1 antibody and C unlabeled oligoprobe.
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Figure 2: Runx1 regulates Rspo3 expression. (A–F) LM3 and MDA-MB-231 cells were transfected with DN or C. (A) Western blot 
(WB) showing tag flag expression in LM3 cells 48 h after transfection. Asterisk indicates specific band. (B) Luciferase assays on LM3 cells 
48 h after co-transfection with DN or C and a reporter vector of Runx1 activity (Luc-R1) or empty vector, as control (Luc-C). Bar graph 
showing mean and SD of three independent experiments (p = 0,0052) (C–D) Rspo3 mRNA levels by semi-quantitative RT-PCR (C) and 
protein by WB (D) on LM3 cells 48 h after transfection. Bar graph showing mean and SD of three independent experiments (p = 0.014 
and (p = 0,007). (E) Rspo3 protein secretion levels by WB of conditioned media generated by LM3 cells 48 h after transfection. Values 
were normalized to the number of cells after transfection. Bar graph showing mean and SD of three experiments (p = 0.021). (F) RSPO3 
protein levels by WB analysis on MDA-MB-231 48 h after transfection. Bar graph showing mean and SD of three independent experiments 
(p = 0.0047). (G) SCP2 cells were transfected with a vector containing full Runx1 cDNA (R1) or empty vector as control (C) and WB 
analysis of Runx1 (first line), Rspo3 (second line), Flag tag (third line) and Actb (fourth line, used as loading control) were performed. 
Asterisk indicates specific band. Bar graph shows WB quantification, C in grey columns and R1 in black columns. Bar graph showing mean 
and SD of three independent experiments (p = 0,042).
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Foxp3 blocks Runx1 transcriptional activity in 
mammary epithelial cells
The SCp2 cell line showed visible mRNA levels 
of Foxp3, while Rspo3 endogenous expression was 
undetectable (Supplementary Figure 1A). Figure 1C 
also shows that in these cells, differently to what we 
have observed in LM3 cells, a lesser Runx1 binding to 
its consensus sequences. To study whether endogenous 
Foxp3 might be responsible for inhibition of Runx1 binding 
to the DNA, we evaluated Runx1 transcriptional activity 
after transfecting SCp2 cells with either Foxp3 (siF) or 
control (siC) siRNAs. Figure 4A and 4B show that Foxp3 
is downregulated in SCp2 siF-transfected cells, while 
Runx1 expression levels are not modified (Figure 4A). 
Knockdown of Foxp3 in SCp2 cells led to a decrease in p21 
expression (Figure 4A), a known Foxp3 target gene [33] 
and significantly prompted SCp2 proliferation, previously 
described in vivo in [33] (Figure 4D). Importantly, our results 
show that Foxp3 downregulation resulted in a significantly 
enhanced Runx1 transcriptional activity (Figure 4C) and 
Rspo3 expression induction (Figure 4E and 4F).
Figure 3: Runx1 physically interacts with Foxp3 in normal mammary epithelial cells. (A) Total protein extracts from 
SCp2 cells were incubated with anti-Foxp3 antibody and subsequent precipitation products were analyzed with anti-Runx1 antibody by 
WB analysis. IP (+) lane shows Runx1 co-immunoprecipitated with Foxp3. (B) Immunofluorescence of  SCp2 cells shows subcellular 
localization of Runx1 (green) and Foxp3 (red) by confocal microscopy. Merge and inset figures show yellow dots representing co-
localization of Runx1 and Foxp3 proteins. Magnification bar: 50 μm.
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Figure 4: Foxp3 blocks Runx1 transcriptional activity. SCp2 cells were transfected with specific Foxp3 siRNA (siF) or scrambled 
control (siC) and mRNA or total protein extracts were analyzed. (A) Downregulation of Foxp3 levels (p = 0.004) (left), Runx1 (middle) 
and p21 (right) (p = 0.042) expression by RT-qPCR. (B) Downregulation of Foxp3 levels by WB (p = 0.013), Gapdh expression was 
used as loading control. (C) SCp2 cells were co-transfected with Luc-R1 or Luc-C and luciferase assay was performed (p = 0.028). 
(D) Proliferation assay was performed by counting cell number after siF and siC treatment (ANOVA p < 0.0001). Different letters means 
significant differences p < 0.05 by Bonferroni contrast. (E–F) Rspo3 expression by WB (p = 0.016) (E) and by PCR (p = 0.0059) (F) upon 
siF or siC treatment. Actd expression was used as loading control. Images were analyzed with image J software. In each case histogram 
shows mean and SD of three independent experiments, siC in grey bars and siF in black bars. (G–I) LM3 cells were incubated with 
Anisomycin and total protein or RNA extracts were analyzed 2 h after treatment. (G) RT-qPCR of Foxp3 (p = 0.04) (left) and Runx1 (right) 
were normalized to actin levels in Anisomycin treated (black bars) and control (gray bars) cells. (H) WB of Foxp3 with (black bars) or 
without (gray bars) Anisomycin and Gapdh was used as loading control (p = 0.022). (I) Rspo3 expression by RT-PCR. Histogram shows 
semi-quantification of the intensity of the band from three independent assays performed with vehicle (gray bars) or Anisomycin (black 
bars) (p = 0.012).
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In addition, to determine whether induction of Foxp3 
expression may result in inhibition of Runx1 target genes 
expression in mammary tumor cells (LM3 cells), which 
show low levels of Foxp3 (Supplementary Figure 1), 
were treated with low doses of anisomycin which is able 
to upregulate Foxp3 expression in mammary epithelial 
cell lines (Figure 4G) by c-Jun and ATF-2 activation [34]. 
Figure 4G–4I) shows that anisomycin treatment of LM3 
cells caused a decrease in Rspo3 expression (4H–4I) 
without affecting the levels of Runx1 mRNA (4G). 
Taken together, these experiments indicate that 
Foxp3 might be able to impair Runx1 transcriptional 
activity in normal mammary epithelial cells. In tumor cells 
Foxp3 low expression would explain high transcriptional 
activity of Runx1 on Rspo3 promoter. Furthermore, these 
data strongly suggest that Foxp3 and Runx1 protein 
interaction could determine Runx1 tumor promotion 
transcriptional activity in mammary epithelial cells. 
Moreover, our data propose a new tumor suppressor role 
for Foxp3 in mammary epithelial cells. 
Impaired Runx1 activity reduces migration  
of breast tumor cells and upregulates  
GJA1 gene expression
As tumor metastasis is the main cause of morbidity 
and mortality, we explored the ability of Runx1 to promote 
tumor aggressiveness. To address this question we studied 
migration capacity of DN/Runx1 (DN) transfected tumor 
cells (LM3 and MDA-MB-231) by in vitro scrape-
wound closure assays. Our results show that Runx1 
inhibition resulted in a lower ability to fill the area by cell 
migration (Figure 5A and 5B). In addition, reduction in 
Runx1 transcriptional activity was also accompanied by 
a reduced number of cells (Figure 5C) but no changes in 
apoptosis levels (Figure 5D), indicating that Runx1 might 
be involved in cell cycle regulation without inducing cell 
death. 
Since Runx1 is a potent regulator of gene 
transcription in different cell types [1, 4, 5, 7, 35], we 
hypothesized that the effect observed when tumor cells 
expressed the DN/Runx1 might have a wider effect on 
genome expression of breast cancer cells. Therefore, we 
performed an in silico analysis that provided us a list 
of Runx1 probable target genes that were classified by 
their biological functions using Gene Ontology database. 
Only those previously described in breast cancer were 
selected (MS Recouvreux, unpublished data). This 
approach revealed that Runx1 is potentially able to 
regulate Gja1 (Supplementary Table 1) among other genes 
(MS Recouvreux et al, unpublished data). Interestingly, 
GJA1 has been described as a tumor-suppressor gene, 
which is able to reduce migration and proliferation of 
MCF7 and MDA-MB-231 breast cancer cells [24, 36]. 
Moreover, differential expression of GJA1 has been 
recently described as a potential positive prognostic 
marker for a clinically relevant stratification of breast 
cancer [23]. LM3 cells show lower levels of Gja1 mRNA 
compared with SCp2 cell line (Supplementary Figure 1B). 
By ChIP assays we demonstrate that Runx1 is able to bind 
GJA1 promoter region in MDA-MB-231 (Figure 6A). 
Moreover, DN/Runx1-transfected tumor cells showed 
a significant upregulation of GJA1 in this cell line 
demonstrating an inhibitory role of Runx1 on GJA1 
promoter (Figure 6B). These results strongly suggest that 
Runx1 is able to inhibit GJA1 gene expression in human 
breast tumor cells. To show that FOXP3 is interfering with 
RUNX1 transcriptional inhibitory activity on GJA1 gene, 
we proceed to knockdown Foxp3 expression in SCp2 
cells. To evaluate if Foxp3 is also able to interfere with 
Runx1 transcriptional inhibitory activity, we evaluated 
GJA1 expression in Foxp3 knockdown cells. Interestingly, 
reduced Foxp3 gene expression in SCp2 cell line showed 
a significant reduction of Gja1 gene expression compared 
with transfected control cells (Figure 6C). Therefore, we 
propose that GJA1 is a target of Runx1 transcriptional 
inhibitory activity, which is repressed by Foxp3 in 
mammary epithelial cells. 
Collectively, these observations indicate that a 
decreased in the availability of Foxp3 could cause a 
decisive increase in Runx1 transcriptional activity, which 
may alter migration abilities of tumor cells by binding and 
regulating it’s downstream target genes such as Rspo3 
and Gja1. These data strongly suggest that Runx1/Foxp3 
interaction could be a new mechanism of gene expression 
regulation during breast cancer development.
DISCUSSION
In this study we show for the first time that 
endogenous Runx1 and Foxp3 physically interact in 
mammary epithelial cells leading to the inhibition 
of Runx1 transcriptional activity. Furthermore, we 
demonstrate that Runx1 is able to actively promote 
oncogene Rspo3 and prevent GJA1 gene expression in 
mammary tumor cell lines. 
Although Runx1 participation has been widely 
described in the hematopoietic system and leukemia, 
during the last years different studies have indicated that 
this transcription factor could be also involved in other 
cancer types [11]. Particularly, Runx1 has been identified 
as a significant controller of tumorigenesis in various 
epithelial cancers [4, 5, 37]; however, its contribution 
in breast cancer development is still under debate [9]. 
Experimentally, Ras-mediated transformation of mammary 
epithelial cells (MCF10A) has been shown to be associated 
with loss of Runx1 expression [10]. Other report by 
Wang and colleagues indicated that RUNX1 knockdown 
causes hyperproliferation and abnormal morphogenesis in 
MCF10A-5E cell clone [12]. These authors also show that 
RUNX1 downregulation is associated with compensatory 
upregulation of FOXO1, since RUNX1-depleted cells 
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require normal FOXO function for proliferation [12]. Our 
work shows by lost-of-function assays that Runx1 is able 
to modulate mammary gene expression towards a cancer 
behavior fate. Our data indicates that reduced Runx1 
transcriptional activity downregulates Rspo3 oncogene 
expression, upregulates GJA1 tumor suppressor gene 
expression, significantly delays tumor cell migration and 
wanes cell number, in a susceptible manner to Foxp3’s 
stalling activity. These results suggest that Runx1 could 
be acting as a tumor enhancer depending on Foxp3 
availability. The difference observed between our study 
and the ones described above could be explained by 
different genetic background and/or because of the 
strategy used. While Wang and colleagues abolished 
RUNX1 expression in an immortalized cell line (MCF10-
A-5E) [12], we reduced RUNX1 transcriptional activity in 
tumor cell lines (LM3 and MDA-DB-231) and upregulated 
its endogenous functional availability in normal epithelial 
cell line (SCp2) by RUNX1 overexpression or Foxp3 
knockdown. It would be interesting to unravel in which 
steps of tumor induction and/or promotion is Runx1 and 
Foxp3 interplay defining cell fate. 
Other authors also described this controversy 
analyzing RUNX1 expression by different techniques 
in human breast tumor samples [13, 38, 39]. Ferrari 
and colleagues performed the first comprehensive 
characterization of RUNX1 protein expression in breast 
cancer by immunohistochemistry using a large cohort 
of human samples [13]. They showed that high Runx1 
protein expression correlated with poor prognosis 
Figure 5: Runx1 is required for tumor cell migration. LM3 cells (A) and MDA-MB-231 cells (B) were subjected to wound healing 
assays for 18 h after transfection with DN or C expression vectors. Time points: 0 h and 18 h. A representative assay (up) and histograms 
(down) show mean and SD of three independent experiments (LM3 p = 0.02; MDA p = 0,0035). (C) LM3 and MDA-MB-231 cell 
number were assessed before and after transfection with DN or C expression vectors. Histogram shows mean and SD of three independent 
experiments (LM3 p = 0.0007; MDA p = 0,03) Axis X is 105 cells. (D) After transfection with DN or C expression vectors, LM3 cells were 
incubated with Annexin V-FITC and PI. Apoptosis was measure by flow citometry. PFA 4% was used as positive control.
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in triple negative breast cancer patients [13]. On the 
other hand, large-scale sequencing studies in human 
breast cancer revealed frequent RUNX1 mutations and 
deletions [38, 39]. This observation could be explained 
by the consideration that if Runx1 is used as a prognostic 
marker should be assessed not only by gene or protein 
expression levels but also by its functional activity. In 
addition to these considerations that might modulate 
Runx1 activity in the nucleus here we show new evidence 
that RUNX1 might be sequestered by Foxp3 blocking its 
activity as a transcriptional regulator. Several studies on 
leukemia have already shown that cell context and cellular 
dosage are relevant for RUNX1 activity [6, 40, 41]. 
In line with this and due to the multiple roles that 
RUNX1 displays, inducing (as for Rspo3) or repressing 
(as for GJA1) gene expression, probably depending on 
the interaction with other regulatory proteins Foxp3 
expression/localization could be additionally used as a 
collaborative marker for prognosis [6]. The hypothesis that 
RUNX1 could affect different steps in tumor promotion 
has also been described in skin cancer where it was found 
that RUNX1 is important for both, tumor initiation and 
progression, while it had been previously shown that 
RUNX1 was not essential for adult tissue maintenance 
[42].
Here we provide evidence that Runx1 could be 
relevant for breast cancer cell survival and migration, 
supporting the idea that Runx1 could act as a tumor 
enhancer. This phenomenon has previously been described 
in ovarian [4] and skin cancer [5], among others epithelial 
neoplasias [3, 35]. In addition a relevant role of Runx1 in 
physiological hematopoietic cell migration and adhesion 
has been reported [43]. Interestingly, it has been shown 
that Runx1 depletion reduced prostate stem cell number 
without significant differences in apoptotic and necrotic 
cell death [44]. During the revision process of this 
manuscript Browne et al. has published experimental data 
that support part of our results [45].
We also demonstrate that GJA1 mRNA levels are 
significantly upregulated when Runx1 transcriptional 
activity is reduced. The participation of GJAs in cancer 
has been studied in vivo and in vitro and results strongly 
suggest that these proteins are less expressed during tumor 
promotion enhancing migration and proliferation [46–49]. 
Moreover, Teleki and colleagues suggest that GJA1 and 
GJA6 could be used as potential positive and negative 
prognostic markers, respectively, for a clinically relevant 
stratification of breast cancers [23]. Furthermore, during 
the writing of this paper Giuliano and colleagues showed, 
using circulating and disseminated tumor cells from 
breast cancer patient-derived xenograft-bearing mice, that 
high GJA1 expression could be used to predict distant 
metastasis-free survival [50]. 
The results showed herein indicate that endogenous 
Foxp3 is able to physically interact with endogenous 
Runx1 in mammary epithelial cells, modulating its 
transcriptional activity. Ono and colleagues describe 
for the first time a physical interaction of Runx1/Foxp3 
in normal regulatory T cells [8]. Our data show that 
downregulation of Foxp3 expression in mammary 
epithelial cells induces Runx1 transcriptional activity, 
which then upregulates RSPO3 and reduces GJA1 gene 
expression without increasing RUNX1 expression. 
Likewise, we demonstrate that upregulation of Foxp3 
expression in mammary tumor cells reduces Rspo3 gene 
expression. It has been proposed that FOXP3 participates 
in breast cancer development as a tumor suppressor 
factor directly bound to its oncogene and miR-146a 
promoter targets [15, 19]. Our in silico analyses revealed 
an absence of Foxp3 binding site in RSPO3 and GJA1 
Figure 6: Runx1 downregulates GJA1 gene expression in the absence of Foxp3. (A) ChIP assays were performed on 
MDA-MB-231 cells using specific ChIP-grade RUNX1 antibody or control IgG. Primers targeting RUNX1 high affinity binding site 
included in the GJA1’s promoter region were designed. Histogram shows mean and SD of three independent experiments performed by 
triplicate. Primers for GAPDH promoter region were used as negative control with no amplification product. Primers for KCTD promoter 
region were used as positive control previously described in [58] (KCTD: Potassium Channel Tetramerization Domain). Anti-Runx1 
antibody is in grey bars and Anti-IgG antibody is in black bars. (B) GJA1 mRNA levels by qPCR of MDA-MB-231 transfected cells 
with DN or C expression vector. Histograms represent mean and SD of three independent experiments (p = 0.004). (C) SCp2 cells were 
transfected with specific Foxp3 siRNA (siF) or scrambled control (siC) and GJA1 gene expression was measured by RT-qPCR. Histograms 
represent mean and SD of three independent experiments (p = 0.03).
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promoter regions. It has been shown that prognostic value 
of FOXP3 in breast cancer depends on localization of this 
protein as well as HER2 and ER expression [17]. Zuo and 
colleagues showed a high proportion of somatic mutations 
and deletions in FOXP3 gene in human breast cancer 
cells, which may include nuclear localization signals [15]. 
In agreement with our experimental data, accumulating 
evidence point out that FOXP3 activity is coordinated with 
multiple transcriptional regulators and Foxp3 localization 
may also depend on its molecular partners [51, 52]. Taken 
together these evidences suggest that Foxp3 localization 
could also define Runx1 activity in mammary epithelial 
cells [18]. Furthermore, our data strongly suggests this 
interaction as a new tumor suppressor mechanism used by 
Foxp3 to reduce breast tumor promotion.
These results strongly suggest that Runx1/Foxp3 
physical interaction in mammary epithelial cells is a 
relevant mechanism to regulate gene expression that 
controls cell fate. In vivo experiments will allow us to test 
this hypothesis evaluating tumor initiation, stemness and 
metastatic models considering tumor microenvironment. 
Finally, facilitate Runx1/Foxp3 interaction could be use 
to improve anti-tumor strategies in breast cancer therapy. 
MATERIALS AND METHODS
Cell lines
LM3 is a mouse mammary cancer cell line derived 
from a spontaneous malign adenocarcinoma from a 
BALB/c strain in the animal care area of Oncology Institute 
Angel H. Roffo (Argentina). This cell line was kindly 
given by Elisa Bal De Kier, Oncology Institute Angel H. 
Roffo. [29, 30, 53, 54]. Cells were grown in MEM (Gibco). 
SCp2 is a mouse mammary immortalized cell line kindly 
given by Dr. Mina Bissell, Lawrence Berkeley National 
Laboratory, Berkeley, USA [32]. Cells were routinely 
grown in DMEM/F12 (Gibco) supplemented with 2% 
FBS, 5 μg/ml insulin. MDA-MB-231 [55] (ATCC® 
HTB- 26™) is a human breast cancer cell line routinely 
grown in RPMI (Gibco). All cell line were grown with 
10% FBS (Internegocios SA), unless specified, 100 U/ ml 
of penicillin and 100 µg/ml of streptomycin. Cells were 
kept at low passages and store at liquid nitrogen.
In silico promoter analysis
We used database sites available on line (http://
www.genomatix.de/ and http://www.cbrc.jp/research/db/
TFSEARCH.html) to determine the presence of putative 
binding sites for the transcription factor Runx1 (TGTGGT 
of high affinity) at the promoter region of Rspo3 and Gja1 
promoter region (–5000 bp up stream from +1 transcription 
site, Supplementary Table 1). No Foxp3 binding sites 
(consensus sequence: A/GTAAACAA) were found. 
Transient transfection assays and treatments
For transient transfections, 3 × 105 cells were 
plated in medium without antibiotics and 24 h later were 
transfected with different vectors or siRNA as indicated: 
pCDNA3-DN: vector containing a dominant negative 
version of Runx1 (DN) subcloned from pMSCV2.2 using 
Bgl II and EcoR I enzymes; pCDNA3: control empty 
vector (C); pGL3-RORyT: a reporter plasmid containing 
the promoter of RORyT with putative sites for Runx1 
upstream luciferase gene (Luc-R1) kindly given by V 
Lazarevic [56] (NIH, USA); pGL3: control vector without 
Runx1 binding sites (Luc-C); siRNA and Stealth RNAi™ 
siRNA Duplex oligoribonucleotide (Invitrogen) Foxp3: 
oligonucleotide containing a specific sequence to block 
Foxp3 transcription (siF); siRNA Control: oligonucleotide 
with scrambled sequence (siC) (sequences upon request). 
We used β-Gal vector as transfection control and 
TK-renilla vector for luciferase assays. Transfection assays 
were performed using Lipofectamine 2000 (Invitrogen) 
and OptiMEM (Life Technologies). After 48 h cells were 
harvested in lysis buffer. Luciferase levels were normalized 
to renilla expression measured with Promega luciferase/
renilla kit according to the manufacturer protocol. β-Gal 
activity was measured by absorbance at 515 nm in 
spectrophotometer (BIORAD). For proliferation assay 
cells were harvested at 24, 48 or 72 hours after siRNA 
transfection. Cells were stained with bromophenol blue for 
viability and counted in Neubauer chamber.
Dominant negative version of Runx1 (DN) was 
generated introducing a stop codon at 826 cDNA 
sequence position included in the transactivation 
domain. This results in early translation termination 
and a short version of Runx1 behaving as a dominant 
negative over Runx1 during homodimerization. 
For Foxp3 overexpression, LM3 cells were 
incubated with 0.05 μg/ul of Anisomycin (SIGMA) or 
vehicle (ethanol) as previously described [34].
Immunofluorescence and confocal microscopy
SCp2 cells were fixed with 4% paraformaldehyde 
for 15 minutes at room temperature (RT), washed in 
PBS-tween 0.05% (PBS-T). Cells were permeabilized 
with 0.1% of Triton X-100 for 10 minutes at RT, and 
blocked with 2% BSA in PBS-T (blocking solution) for 
1 h. After blocking, cells were incubated for 1 h at RT 
with anti-FOXP3 (SC-28705) or anti-Runx1 antibodies 
(SC-8564) in blocking solution. Cells were washed in 
PBS and incubated for 1 h at RT with anti goat-Cy5 
(Santa Cruz) and anti rabbit-Cy3 (Santa Cruz), Dapi 
and phalloidin (Life Technologies) in blocking solution. 
After washes in PBS, coverslips were mounted with 
gelvatol. Images were taken at LSM510 Meta confocal 
microscope (Carl Zeiss). 
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Co-immunoprecipitation assay
For immunoprecipitation SCp2 were washed, lysed, 
and pre-cleared with 20 µl A/G plus Agarose (Agarose, 
Santa Cruz) at 4ºC for 30 minutes, and centrifuged at 
1000 g for 5 minutes. Supernatant was incubated with or 
without 1 µl of Foxp3 primary antibody (SC-28705) and 
20 µl of Agarose at 4ºC. Immunoprecipitates were pelleted 
by centrifugation (1000 g, 5 minutes, 4ºC), washed with 
PBS, and prepared for western blot (WB).
Chromatin immunoprecipitation assays
LM3 and MDA-MD-231 cell lines were used for 
chromatin immunoprecipitation (ChIP) assays. ChIP 
were performed as previously described [57] using anti-
RUNX1 (Abcam 23980) and anti-IgG (Abcam 46540, 
negative control). Quantification of ChIP was performed 
by real-time polymerase chain reaction (qPCR) using 
Stratagene Mx3000P™ instrument. The fold enrichment 
of target sequence in the immunoprecipitated compared 
with input fractions was calculated using the comparative 
Ct (the number of cycles required to reach a threshold 
concentration) method with the equation 2(DCt (ref)-DCt (t)). 
Each of these values were corrected by mouse GAPDH 
gene and referred as relative abundance over time zero. 
Primers sequences are available on request. 
Protein analysis
Total proteins were extracted from mammary 
tissue in lysis buffer supplemented with protease 
cocktail set I (Calbiochem). Proteins were resolved in 
10 or 12% polyacrylamide gel, and transferred to a poly-
vinylidine fluoride membrane. Primary antibodies: β-actin 
(SC-1616-R), Foxp3 (Abcam 14551), Runx1 (Abcam 
61753), RSPO3 (R & D MAB41201), GAPDH (Abcam 
9483), FLAG (Sigma F3165). Secondary antibodies: 
rabbit IgG (SC-2004), mouse IgG (SC-2005), rat IgG 
(SC-2006). The immune reactive protein bands were 
detected using chemiluminescence system (ECL_Plus 
system; GE) and the Fuji Film Image Reader (LAS-1000 
Fuji Film). Densitometric analysis of protein levels was 
performed with ImageJ 1.34s software (Wayne Rasband, 
NIH). In each case obtained values were normalized as 
indicated in each experiment.
RNA analysis
RNA was extracted from cellular lysates with Trizol 
reagent (Invitrogen) according to the manufacturer’s 
instructions. For reverse transcription, 1 μg of total RNA 
was used. Retrotranscription was performed at 37ºC 
for 60 minutes followed by 15 minutes at 72ºC. For the 
quantitative real-time RT-PCR (qRT-PCR) 1 µl cDNA was 
used. All reactions were placed at Stratagene Mx3000P™ 
Instrument. Primers are available upon request. Reactions 
were run for 35 cycles under the following conditions: 15 
seconds at 94ºC, 20 seconds at 58ºC–65ºC (according to 
the primers), and 20 seconds at 72ºC. The amplification of 
unique products in each reaction was verified by melting 
curve. Expression level of each gene was normalized to 
actin expression level using delta Ct method and specific 
primers. Means and standard deviation (SD) from at 
least three experiments were calculated and shown as 
fold changes with respect to the control. RSPO3 gene 
expression was analyzed by RT-PCR using MJ Research 
MiniCycler™ or Lambeth Multigene getting the same 
results on both machines. PCR products were visualized 
on 2% gel with ethidium bromide. Rspo3 expected band 
is 400 bp and 200 bp for Actin. 
In vitro wound-healing repair assays
Cells were grown in normal growth media to 
monolayer confluence. Scratches were performed with a 
tip, and cell debris was removed by washing with PBS. 
Width of each wounded area was measured using grids at 
three marked positions photographed (40x magnification) 
at the indicated times. Cell migration was quantified as the 
distance covered by cells in wound-healed surface from 
the marked positions. Results are expressed as mean ± SD 
of three independent experiments.
Apoptosis assays
After 48 h of Lipofectamine transfection with Runx1 
dominant negative (DN), control (C) expression vectors 
used or after 24 h incubation with 4% PFA, cells were 
incubated with Annexin V-FITC and Propidium Iodide 
(BD) for 10 minutes on ice. Apoptosis was analyzed by 
flow cytometer (BD FACS-Aria II). Data were processed 
using FlowJo software (Tree Star). Percentage of early 
plus late apoptotic cells was calculated as the ratio 
between Annexin-V FITC/PI- stained cells and total 
number of cells.
Statistical analysis
Results were expressed as mean with SD as 
indicated in Figure legends. Differences were regarded as 
significant at p < 0.05. Statistical analyses were performed 
by Infostat software (Di Rienzo J.A., et al. InfoStat versión 
2012. Grupo InfoStat, FCA, Universidad Nacional de 
Córdoba, Argentina). 
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